Sandu Pharmaceuticals share price

Balanced risk
  • 38%Low risk
  • 38%Moderate risk
  • 38%Balanced risk
  • 38%High risk
  • 38%Extreme risk
  • ₹53.30(-1.39%)
    April 24, 2025 15:02:53 PM IST
    • NSE
    • BSE
  • Vol : 1.18K (NSE + BSE)
    Last 20 day avg : 11.38 K

Sandu Pharmaceuticals is trading -1.39% lower at Rs 53.30 as compared to its last closing price. Sandu Pharmaceuticals has been trading in the price range of 54.00 & 52.40. Sandu Pharmaceuticals has given -5.61% in this year & 10.08% in the last 5 days. Sandu Pharmaceuticals has TTM P/E ratio 15.92 as compared to the sector P/E of 49.56.The company posted a net profit of 0.56 Crores in its last quarter.Listed peers of Sandu Pharmaceuticals include Jeevan Scientific Technology (-1.60%), Crestchem (1.50%), Sandu Pharmaceuticals (-1.39%).The Mutual Fund holding in Sandu Pharmaceuticals was at -% in . The MF holding has - from the last quarter. The FII holding in Sandu Pharmaceuticals was at -% in . The FII holding has - from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Key Metrics

Updated on Apr 24, 2025, 02:31 PM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    1.48
    Higher than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    1.29
    In line with historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    15.03
    Lower than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.99
    Medium volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.00
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
52.40
Highest
54.00
52 week range
Lowest
43.75
Highest
69.50
Sandu Pharmaceuticals Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in December quarter by 5.42% from Rs 18.37 crore to Rs 17.43 crore, year-on-year
    • financial-insightsThe company has grown its December quarter profit by 169.01% from Rs 0.21 crore to Rs 0.56 crore, year-on-year
    • financial-insightsThe debt to equity of the company is lower than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Sandu Pharmaceuticals Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 55.01
  • R2
  • 61.03
  • R3
  • 66.66
Pivot49.38
  • S1
  • 43.36
  • S2
  • 37.73
  • S3
  • 31.71
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Sandu Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Jeevan Scientific Technology
Neutral
42.35-1.6067.05-1.4-19.86
Crestchem
Bullish
226.751.5068.0329.7413.030.23-
Sandu Pharmaceuticals
Neutral
53.30-1.3951.5435.021.261.510.15
Deccan Health Care
Neutral
20.001.1646.5424.620.42-1.73
Gujarat Terce Laboratories
Bearish
61.00-1.5043.49187.466.42-13.05
Sandu Pharmaceuticals Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Sandu Pharmaceuticals is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPromoter(s) holding is moderate at 42.90%
    • InsightsFIIs are not invested in this company
    • InsightsMutual Funds are not invested in this company.
    Sandu Pharmaceuticals Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-02-13Quarterly Results
    2024-11-14Quarterly Results
    2024-08-12Quarterly Results & Final Dividend
    2024-06-05Audited Results
    2024-05-30Audited Results
    About the company Sandu Pharmaceuticals
    • IndustryBiotechnology & Drugs
    • ISININE751D01014
    • BSE Code524703
    • NSE Code
    Sandu Pharmaceuticals Limited is an India-based company, which is mainly engaged in the business of manufacturing and trading of ayurvedic medicines under the brand name, SANDU. The Company's product category includes digestive health, immunity, muscle and bone health, respiratory health, wellness, and others. Its digestive health products focus on constipation, hyperacidity, indigestion and flatulence, and loose motions, among others. Its wellness products cover female wellness, male wellness and mother and child. Its respiratory health products focus on respiratory health, asthma, and cold and cough. Its ayurveda category includes herbs, panchakarma, dincharya, rutucharya, ahar vihar, arogyadarshika, prakruti and yoga. The Company also offers products, such as an immunity kit and a power herbs range. Its products are manufactured using in-house know-how supplied by Sandu Brothers Private Limited. The Company's products are sold through e-commerce marketplaces.
    • Management Info
    • Vijay KajrekarChief Financial Officer
    • Pratika MhambrayCompliance Officer, Company Secretary
    • Umesh SanduManaging Director, Executive Director
    Sandu Pharmaceuticals Share Price FAQs

    Sandu Pharmaceuticals is trading at 53.30 as on Thu Apr 24 2025 09:32:53. This is -1.39% lower as compared to its previous closing price of 54.05.

    The market capitalization of Sandu Pharmaceuticals is 51.54 Cr as on Thu Apr 24 2025 09:32:53.

    The 52 wk high for Sandu Pharmaceuticals is 69.50 whereas the 52 wk low is 43.75

    Sandu Pharmaceuticals can be analyzed on the following key metrics -

    • TTM P/E: 15.92
    • Sector P/E: 49.56
    • Dividend Yield: 1.48%
    • D/E ratio: -

    Sandu Pharmaceuticals reported a net profit of 1.46 Cr in 2024.

    Quick Links
    EQUITY QUICK LINKS
    Sandu Pharmaceuticals QUICK LINKS
    FROM MARKETS
    RELATED LINKS
    Quarterly Results
    Business News/Market/Market Stats/   Sandu Pharmaceuticals share price

    Wait for it…

    Log in to our website to save your bookmarks. It'll just take a moment.